Oxbridge Re Holdings Limited | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (10)

Latest Posts

About This Stock More About This Stock
Protalix BioTherapeutics Announces FDA Acceptance Of BLA For The Treatment Of Fabry Disease And Grants Priority Review
Article By: TalkMarkets Newswire
Tuesday, August 11, 2020 9:05 AM EDT
Priority Review is granted to therapies that the FDA determines have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions.
In this article: PLX Also: IMMP, SRNE, TTOO, OPGN, OXBR
Read

Latest Tweets for $OXBR

No tweets yet!

PARTNER HEADLINES